A deep dive into the Fc–FcR axis as a therapeutic anchor in autoimmune disease, examining immune signaling and drug ...

Please provide your email address to receive an email when new articles are posted on . Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SCOTTSDALE, Ariz. — A novel therapeutic approach ...

Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis. A new review of the latest therapies for myasthenia gravis (MG), including ...